James H. Stanker - Nov 1, 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Financial Officer
Signature
/s/ James H. Stanker by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Nov 1, 2021
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 05:46 PM
Previous filing
Jan 6, 2022
Next filing
Jan 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 -4.29K -13.67% $0.00 27.1K Nov 1, 2021 Common Stock 4.29K $0.00 Direct F1
transaction PCSA Restricted Stock Units Award $0 -10.7K -22.09% $0.00 37.8K Mar 31, 2022 Common Stock 10.7K $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.